MedTrace Logo

Vasopressor Prophylaxis After Spinal Anesthesia

NCT03234816 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 270

Last updated 2019-01-15

No results posted yet for this study

Summary

Norepinephrine has been recently introduced as a prophylactic vasopressor during Cesarean delivery with promising results ; However, the optimum dose for efficient prophylaxis with the least side effects is not known. In this study, we will compare three doses (0.05, 0.1, 0.15 mcg/Kg/min) of norepinephrine for prophylaxis against Post-Spinal hypotension during cesarean delivery.

Conditions

  • Cesarean Section Complications

Interventions

DRUG

Norepinephrine 0.05 mcg /Kg/min

Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia

DRUG

Norepinephrine 0.1 mcg /Kg/min

Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia

DRUG

Norepinephrine 0.15 mcg /Kg/min

Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia

DRUG

Bupivacaine

10 mg Bupivacaine intra-thecal for spinal anesthesia

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Ahmed Mukhtar, Professor · Head of research committee section in anesthesia department

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-02
Primary Completion
2018-11-02
Completion
2018-12-10

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03234816 on ClinicalTrials.gov